{"nctId":"NCT02545049","briefTitle":"Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease","startDateStruct":{"date":"2015-09-17","type":"ACTUAL"},"conditions":["Diabetic Kidney Disease"],"count":7352,"armGroups":[{"label":"BAY94-8862","type":"EXPERIMENTAL","interventionNames":["Drug: Finerenone (BAY94-8862)"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Finerenone (BAY94-8862)","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Men or women ≥18 years of age\n* Subjects with Type Type 2 Diabetes Mellitus as defined by the American Diabetes Association\n* Diagnosis of Diabetic Kidney Disease with persistent high albuminuria or persistent very high albuminuria at the Run-In and Screening Visit\n* Pretreated with either angiotensin-converting enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB) at maximal tolerated labeled dose without adjustments\n* Serum potassium \\<=4.8 mmol/L\n\nExclusion Criteria:\n\n* Confirmed significant non-diabetic renal disease, including clinically relevant renal artery stenosis\n* Uncontrolled arterial hypertension (ie, mean sitting systolic blood pressure (SBP) ≥170 mmHg or mean sitting diastolic blood pressure(DBP) ≥110 mmHg at run in visit, or mean sitting SBP ≥160 mmHg or mean sitting DBP ≥100 mmHg at screening)\n* Clinical diagnosis of chronic heart failure with reduced ejection fraction (HFrEF) and persistent symptoms {New York Heart Association (NYHA) class II - IV} at Run in visit \\[class 1A recommendation for mineralcorticoid receptor antagonist (MRAs)\\]\n* Dialysis for acute renal failure within 12 weeks of Run-in visit\n* Renal allograft in place or scheduled kidney transplant within next 12 months\n* Glycated hemoglobin (HbA1c) \\>12%","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The First Occurrence of the Composite Endpoint of Cardiovascular Death, Non-fatal Myocardial Infarction, Non Fatal Stroke, or Hospitalization for Heart Failure.","description":"Number of participants with the first occurrence of the primary cardiovascular (CV) composite outcome, CV death, non-fatal myocardial infarction (MI), non-fatal stroke, or hospitalization for heart failure were reported as descriptive result.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"458","spread":null},{"groupId":"OG001","value":"519","spread":null}]}]}]},{"type":"SECONDARY","title":"The First Occurrence of the Composite Endpoint of Onset of Kidney Failure, a Sustained Decrease of eGFR ≥40% From Baseline Over at Least 4 Weeks, or Renal Death.","description":"Number of participants with first occurrence of the composite endpoint of onset of kidney failure, a sustained decrease of eGFR ≥40% from baseline over at least 4 weeks, or renal death were reported as descriptive result.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"350","spread":null},{"groupId":"OG001","value":"395","spread":null}]}]}]},{"type":"SECONDARY","title":"All-cause Hospitalization","description":"Number of participants with first occurrence of a hospitalization event were reported as descriptive result.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1573","spread":null},{"groupId":"OG001","value":"1605","spread":null}]}]}]},{"type":"SECONDARY","title":"All-cause Mortality","description":"Number of participants with death due to any cause were reported as descriptive result. Number of participants with outcome death reported here includes deaths occurred after randomization until the end of the study visit. Deaths after end of study visit are not included in this table.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"333","spread":null},{"groupId":"OG001","value":"370","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Urinary Albumin-to-creatine Ratio (UCAR) From Baseline to Month 4","description":"First morning void urine samples were collected to evaluate the urinary albumin-to-creatinine ratio (UACR). Month 4 was the visit closest to day 120 within a time window of 120 ± 30 days after randomization. If no measurements were available in this time window, the participant was excluded from this analysis. Ratio of UACR at Month 4 to UACR at baseline is reported as the change.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.624","spread":null},{"groupId":"OG001","value":"0.922","spread":null}]}]}]},{"type":"SECONDARY","title":"The First Occurrence of the Composite Endpoint of Onset of Kidney Failure, a Sustained Decrease in eGFR of ≥57% From Baseline Over at Least 4 Weeks, or Renal Death","description":"Number of participants with first occurrence of the renal composite outcome, onset of kidney failure, a sustained decrease in eGFR of ≥57% from baseline over at least 4 weeks, or renal death were reported as descriptive result.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"108","spread":null},{"groupId":"OG001","value":"139","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1158,"n":3683},"commonTop":["Nasopharyngitis","Arthralgia","Back pain","Hypertension","Hyperkalaemia"]}}}